ABSTRACT
OASIS-3 is a compilation of MRI and PET imaging and related clinical data for 1098 participants who were collected across several ongoing studies in the Washington University Knight Alzheimer Disease Research Center over the course of 15 years. Participants include 605 cognitively normal adults and 493 individuals at various stages of cognitive decline ranging in age from 42 to 95 years. The OASIS-3 dataset contains over 2000 MR sessions, including multiple structural and functional sequences. PET metabolic and amyloid imaging includes over 1500 raw imaging scans and the accompanying post-processed files from the PET Unified Pipeline (PUP) are also available in OASIS-3. OASIS-3 also contains post-processed imaging data such as volumetric segmentations and PET analyses. Imaging data is accompanied by dementia and APOE status and longitudinal clinical and cognitive outcomes. OASIS-3 is available as an open access data set to the scientific community to answer questions related to healthy aging and dementia.
Competing Interest Statement
Authors P.J.L., S.K., R.H., E.G., C.X., J.H., K.M., A.G.V., M.E.R., C.C. declare no competing interests. J.C.M. is funded by NIH grants # P50AG005681; P01AG003991; P01AG026276 and UF1AG032438. Neither J.C.M. nor his family owns stock or has equity interest (outside of mutual funds or other externally directed accounts) in any pharmaceutical or biotechnology company. T.L.S.B. Participated in clinical trials sponsored by Eli Lilly, Roche, and Biogen. Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly) provided T.L.S.B. doses of 18F-florbetapir, partial funding for 18F-florbetapir scanning, precursor for 18F-flortaucipir and technology transfer for manufacturing of 18F-flortaucipir).
Funding Statement
Funding for the Knight ADRC and KARI were provided by NIH P50AG00561, P30NS09857781, P01AG026276, P01AG003991, R01AG043434, R01AG054567, UL1TR000448, and R01EB009352. Florbetapir doses were provided by Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
OASIS-3 data is openly available to the scientific community at https://www.oasis-brains.org. Prior to accessing the data, users are required to agree to the OASIS Data Use Terms.
Abbreviations
- AD
- Alzheimer Disease
- ADRC
- Alzheimer Disease Research Center
- APOE
- ASL
- arterial spin labeling
- AV45
- Florbetapir (18F-AV-45)
- BPND
- binding potential
- CDR
- Clinical Dementia Rating
- CSF
- cerebrospinal fluid
- DWI
- diffusion weighted imaging
- DAT
- is outmoded; use “AD dementia” or “symptomatic AD” – the latter term can be stated to encompass both MCI due to AD and AD dementia
- FDG
- fluorodeoxyglucose (18F-FDG)
- BOLD
- blood oxygen level dependent
- MCBP
- mean cortical binding potential
- mCi
- millicurie
- MCSUVR
- mean cortical SUVR
- MRI
- magnetic resonance imaging
- OASIS
- Open Access Series of Imaging Studies
- PiB
- Pittsburgh compound B (11C-PIB)
- PUP
- Pet Unified Pipeline
- PET
- Positron emission tomography
- PVE
- partial volume effects
- QC
- quality control
- rsf
- regional spread function
- SWI
- susceptibility weighted imaging
- SUVR
- standard uptake ratio
- TOF
- time of flight
- UDS
- Uniform Data Set
